PTH (1–34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats

• Published in: Bone (New York, N.Y.) Vol. 53; no. 1; pp. 51 - 58
• Main Authors: Brüel, Annemarie, Vegger, Jens Bay, Raffalt, Anders Christer, Andersen, Jens Enevold Thaulov, Thomsen, Jesper Skovhus
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Inc 01.03.2013; Elsevier
• Subjects: Alkaline Phosphatase - metabolism; Animals; Biological and medical sciences; Biomechanical Phenomena; Body Weight - drug effects; Bone and Bones - drug effects; Bone and Bones - physiopathology; Bone Diseases, Metabolic - physiopathology; Diseases of the osteoarticular system; Female; Fundamental and applied biological sciences. Psychology; Histomorphometry; Immobilization; Mechanics; Medical sciences; Organ Size - drug effects; Organometallic Compounds - pharmacology; Orthopedics; Osteoporosis. Osteomalacia. Paget disease; Parathyroid Hormone - pharmacology; PTH; Rat; Rats; Rats, Wistar; Strontium ranelate; Thiophenes - pharmacology; Tomography, X-Ray Computed; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Strontium ranelate; Immobilization; Mechanics; Rat; Histomorphometry; PTH; Antiosteoporotic; Diseases of the osteoarticular system; Rodentia; Vertebrata; Mammalia; Animal; Morphology; Spongious bone; Osteopenia; Strength; Teriparatide

Abstract PTH and strontium ranelate (SrR) have both been shown to reduce bone loss induced by immobilization. PTH is a potent bone anabolic agent, whereas SrR has been suggested to be an antiresorptive as well as a bone anabolic agent. The aim of the study was to investigate whether PTH, SrR, and PT...